Impact of Primary Chronic Immune Thrombocytopenia and Thrombopoietin Receptor Agonists Treatment Instructions on Daily Living: Results of a Multinational Cross-Sectional Survey.

IF 2 3区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Patient preference and adherence Pub Date : 2025-08-13 eCollection Date: 2025-01-01 DOI:10.2147/PPA.S505337
Jaap Jan Zwaginga, Srikanth Nagalla, Marie Linden, Marjo Hannele Lindberg, Caroline Kruse, Mervyn Morgan, Cecilie Yssing, Donatella Decise, Milica Putnik, Carly Rich
{"title":"Impact of Primary Chronic Immune Thrombocytopenia and Thrombopoietin Receptor Agonists Treatment Instructions on Daily Living: Results of a Multinational Cross-Sectional Survey.","authors":"Jaap Jan Zwaginga, Srikanth Nagalla, Marie Linden, Marjo Hannele Lindberg, Caroline Kruse, Mervyn Morgan, Cecilie Yssing, Donatella Decise, Milica Putnik, Carly Rich","doi":"10.2147/PPA.S505337","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Thrombopoietin receptor agonists (TPO-RAs) are second-line treatments for people with immune thrombocytopenia (ITP). A survey was conducted to evaluate the understanding of and adherence to TPO-RA treatment instructions, and to determine the impact of ITP and TPO-RAs on daily living.</p><p><strong>Patients and methods: </strong>Cross-sectional, self-administered, online survey conducted from September 2023 to April 2024. Respondents were aged ≥18 years, diagnosed with primary chronic ITP, and prescribed a TPO-RA in the last 12 months and for ≥3 months.</p><p><strong>Results: </strong>In total, 221 respondents were voluntarily recruited by patient organizations and completed the survey. Over one-third (37%) of respondents were given ≥5 specific instructions on medication use (eltrombopag 58%; avatrombopag 24%; romiplostim 9%). Taking treatment at the same time each day/week was most common. Eltrombopag-treated respondents were given the most instructions about food: timing of medication relative to meals (72%), timing of meals relative to medication (65%), and the restriction (44%) or avoidance (69%) of certain foods. Despite this, nearly one-third (32%) of eltrombopag-treated respondents ate when/what they wanted at times, and 64% would prefer to have a TPO-RA with no food/drink restrictions. Compared to before ITP diagnosis, living with ITP negatively impacted ≥1 daily activity or mental health in 89% of respondents, most commonly travelling (for pleasure [69%]). Approximately one-third (36%) experienced an improvement or no change in ≥1 daily activity or mental health after TPO-RA treatment initiation. Eating habits, sleeping, exercise/sport and mental health were markedly worsened by treatment with a TPO-RA. Avatrombopag and eltrombopag had the highest rates of any reported improvements across daily activities/mental health.</p><p><strong>Conclusion: </strong>This real-world international survey showed that people with ITP may experience a negative impact on their daily activities and mental health from their condition. Treatment with some TPO-RAs may also impair specific activities, likely influenced by administration routes and dietary restrictions.</p>","PeriodicalId":19972,"journal":{"name":"Patient preference and adherence","volume":"19 ","pages":"2445-2458"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358140/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Patient preference and adherence","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PPA.S505337","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Thrombopoietin receptor agonists (TPO-RAs) are second-line treatments for people with immune thrombocytopenia (ITP). A survey was conducted to evaluate the understanding of and adherence to TPO-RA treatment instructions, and to determine the impact of ITP and TPO-RAs on daily living.

Patients and methods: Cross-sectional, self-administered, online survey conducted from September 2023 to April 2024. Respondents were aged ≥18 years, diagnosed with primary chronic ITP, and prescribed a TPO-RA in the last 12 months and for ≥3 months.

Results: In total, 221 respondents were voluntarily recruited by patient organizations and completed the survey. Over one-third (37%) of respondents were given ≥5 specific instructions on medication use (eltrombopag 58%; avatrombopag 24%; romiplostim 9%). Taking treatment at the same time each day/week was most common. Eltrombopag-treated respondents were given the most instructions about food: timing of medication relative to meals (72%), timing of meals relative to medication (65%), and the restriction (44%) or avoidance (69%) of certain foods. Despite this, nearly one-third (32%) of eltrombopag-treated respondents ate when/what they wanted at times, and 64% would prefer to have a TPO-RA with no food/drink restrictions. Compared to before ITP diagnosis, living with ITP negatively impacted ≥1 daily activity or mental health in 89% of respondents, most commonly travelling (for pleasure [69%]). Approximately one-third (36%) experienced an improvement or no change in ≥1 daily activity or mental health after TPO-RA treatment initiation. Eating habits, sleeping, exercise/sport and mental health were markedly worsened by treatment with a TPO-RA. Avatrombopag and eltrombopag had the highest rates of any reported improvements across daily activities/mental health.

Conclusion: This real-world international survey showed that people with ITP may experience a negative impact on their daily activities and mental health from their condition. Treatment with some TPO-RAs may also impair specific activities, likely influenced by administration routes and dietary restrictions.

Abstract Image

Abstract Image

Abstract Image

原发性慢性免疫性血小板减少症和血小板生成素受体激动剂对日常生活的影响:一项跨国横断面调查的结果。
目的:血小板生成素受体激动剂(TPO-RAs)是免疫性血小板减少症(ITP)患者的二线治疗药物。我们进行了一项调查,以评估对TPO-RA治疗指南的理解和依从性,并确定ITP和TPO-RAs对日常生活的影响。患者和方法:于2023年9月至2024年4月进行横断面、自我管理的在线调查。受访者年龄≥18岁,诊断为原发性慢性ITP,并在过去12个月和≥3个月服用TPO-RA。结果:共有221名被调查者由患者组织自愿招募并完成调查。超过三分之一(37%)的应答者获得了≥5个药物使用的具体说明(艾曲波巴58%;阿瓦曲波巴24%;罗米普罗stim 9%)。每天/每周同一时间接受治疗最为常见。接受eltrombopag治疗的受访者在食物方面得到了最多的指导:服药时间相对于用餐时间(72%),用餐时间相对于服药时间(65%),以及限制(44%)或避免(69%)某些食物。尽管如此,近三分之一(32%)接受电子波包治疗的受访者有时想吃什么就吃什么,64%的人更喜欢没有食物/饮料限制的TPO-RA。与ITP诊断前相比,患有ITP对89%的受访者的日常活动或心理健康产生了负面影响,最常见的是旅行(娱乐[69%])。在TPO-RA治疗开始后,大约三分之一(36%)的患者在≥1次日常活动或心理健康方面有所改善或没有变化。饮食习惯、睡眠、运动/运动和心理健康均因TPO-RA治疗而明显恶化。在日常活动/心理健康方面,阿伐洛巴和伊曲波巴的改善率最高。结论:这项真实世界的国际调查表明,ITP患者的日常活动和心理健康可能会受到负面影响。用一些TPO-RAs治疗也可能损害特定活动,可能受到给药途径和饮食限制的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Patient preference and adherence
Patient preference and adherence MEDICINE, GENERAL & INTERNAL-
CiteScore
3.60
自引率
4.50%
发文量
354
审稿时长
6-12 weeks
期刊介绍: Patient Preference and Adherence is an international, peer reviewed, open access journal that focuses on the growing importance of patient preference and adherence throughout the therapeutic continuum. The journal is characterized by the rapid reporting of reviews, original research, modeling and clinical studies across all therapeutic areas. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal. As of 1st April 2019, Patient Preference and Adherence will no longer consider meta-analyses for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信